Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110311607 | PUNCTAL PLUGS WITH CONTINUOUS OR PULSATILE DRUG RELEASE MECHANISM Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservo... | 12/22/2011 |
| 20110311606 | PUNCTAL PLUGS WITH CONTINUOUS OR PULSATILE DRUG RELEASE MECHANISM Disclosed are lacrimal inserts and their method of use for delivery of of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or rese... | 12/22/2011 |
| 20110268783 | PARTIALLY MICROCELLULAR, SELECTIVELY HYDROPHILIC COMPOSITE CONSTRUCT FOR OCULAR DRUG DELIVERY A partially microcellular, selectively hydrophilic composite as a self-standing construct or a component of a device for ocular delivery of at least one bioactive agent, the composite comprising a highly hydrophilic microcellular foam adjoined with a flexible hydrophobi... | 11/03/2011 |
| 20110262517 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.... | 10/27/2011 |
| 20110236457 | Micronized Device for the Delivery of Biologically Active Molecules and Methods of Use Thereof The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorder... | 09/29/2011 |
| 20110238075 | DRUG DELIVERY DEVICES AND METHODS This disclosure relates generally to methods and devices for use in treating eye conditions with implantable drug delivery devices. One method includes introducing an implant into the suprachoroidal space, wherein the interior volume of the implant is plugged with a dru... | 09/29/2011 |
| 20110182968 | Interpenetrating polymer network hydrogel corneal prosthesis The present invention provides materials that have high glucose and oxygen permeability, strength, water content, and resistance to protein adsorption. The materials include an interpenetrating polymer network (IPN) hydrogel that is coated with biomolecules. The IPN hyd... | 07/28/2011 |
| 20110184358 | PULSATILE PERI-CORNEAL DRUG DELIVERY DEVICE The present invention is directed to a pulsatile ophthalmic peri-corneal drug delivery device. The device includes an annular body and a mechanism for releasing multiple separate and distinct doses of a therapeutic composition over an extended period of time.... | 07/28/2011 |
| 20110159073 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) ... | 06/30/2011 |
| 20110150967 | METHOD OF REDUCING INCIDENCE OF INTRAOCULAR PRESSURE ASSOCIATED WITH INTRAOCULAR USE OF CORTICOSTEROIDS A method of treating an ocular disease in a subject using a corticosteroid with reduced incidence of intraocular pressure lowering surgery comprises injecting an intravitreal insert capable of providing a therapeutic effect for an extended period of time. The intravitre... | 06/23/2011 |
| 20110129516 | OCULAR DRUG DELIVERY DEVICES A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solut... | 06/02/2011 |
| 20110111007 | INHIBITION OF RETINAL CELL DEGENERATION OR NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES The presently claimed and disclosed inventive concept(s) provides methods for reducing, reversing or inhibiting retinal cell degeneration, or neovascularization in tissues of a mammalian subject having a pathological condition involving neovascularization, by administra... | 05/12/2011 |
| 20110091520 | Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta a... | 04/21/2011 |
| 20110076320 | STEM CELL CULTIVATION DEVICES AND METHODS The present invention relates to a device and methods for culturing stem cells, and in particular, for culturing ocular stem cells and the use of stem cells cultured using the devices and methods of the invention for the treatment of diseases.... | 03/31/2011 |
| 20110052493 | USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1 The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A p... | 03/03/2011 |
| 20100330148 | MEHODS AND COMPOSITIONS FOR INHIBITING IMPDH-1 ISOFORM 1 Described herein are methods of inhibiting IMPDH type 1, and treating or preventing a disease or disorder (or symptoms thereof) associated with IMPDH type 1, wherein an IMPDH type 1 inhibitor compound is administered to a subject.... | 12/30/2010 |
| 20100310630 | COATED SURFACE FOR CELL CULTURE The invention makes available a keratin coating of a support substrate and a method for the production thereof. This keratin coating is suitable particularly for the in vitro or in vivo culturing of epithelial or endothelial cells and, because of its optical transparenc... | 12/09/2010 |
| 20100303890 | COPOLYMERS SUITABLE FOR USE IN CORNEAL BANDAGES Disclosed is a polymer having an affinity for corneal cells such that it can be used as a substrate for the growth of corneal cells, and so is suitable for use in a corneal bandage, especially in the form of a contact lens in which at least the cornea contacting surface... | 12/02/2010 |
| 20100278897 | INTRAOCULAR BIOACTIVE AGENT DELIVERY SYSTEM WITH MOLECULAR PARTITIONING SYSTEM The present disclosure generally provides intraocular implants including at least one therapeutic bioactive agent and a molecular partitioning system. The molecular partitioning system comprises at least two phases wherein the first phase has an inherent viscosity equal... | 11/04/2010 |
| 20100272777 | OCULAR THERAPEUTIC AGENT DELIVERY DEVICES AND METHDOS FOR MAKING AND USING SUCH DEVICES Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20<... | 10/28/2010 |
| 20100272780 | CELL LINES THAT PRODUCE PROSTAGLANDIN F2 ALPHA (PGF2a) AND USES THEREOF The invention provides cells and cell lines the are genetically modified to express the hCox-2 enzyme, which, in turn, results in the upregulation of prostaglandin F2 alpha (PGF2a) production. The invention also provides encapsulated cell therapy devices containing such... | 10/28/2010 |
| 20100266664 | Devices And Methods For Ophthalmic Drug Delivery Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a... | 10/21/2010 |
| 20100255061 | Posterior Segment Drug Delivery A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous... | 10/07/2010 |
| 20100239633 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particula... | 09/23/2010 |
| 20100233241 | OPHTHALMIC DRUG DELIVERY SYSTEM AND APPLICATIONS An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially i... | 09/16/2010 |
| 20100233240 | CORNEAL ENDOTHELIAL PREPARATION WHICH ENABLES CELLS TO GROW IN VIVO The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which conta... | 09/16/2010 |
| 20100226962 | PERI-CORNEAL DRUG DELIVERY DEVICE The present invention is directed to an ophthalmic peri-corneal drug delivery device. The device includes a core of matrix material and therapeutic agent and a coating over the core. One or more opening[s] extend through the coating to provide for release of the drug to... | 09/09/2010 |
| 20100215720 | IMPLANTABLE OPTICAL SYSTEM, METHOD FOR DEVELOPING IT AND APPLICATIONS The present invention refers to an implantable optical system comprising a central optical part and an annular anchoring part, where said annular part comprises animals cells, including human cells, that encourage the integration of the implant into the ocular tissue of... | 08/26/2010 |
| 20100209477 | SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other an... | 08/19/2010 |
| 20100209478 | DRUG DELIVERY THROUGH HYDROGEL PLUGS An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass th... | 08/19/2010 |
| 20100189765 | IMPLANTABLE OCULAR DRUG DELIVERY DEVICE AND METHODS The present invention provides implantable ocular drug delivery devices. Generally, the devices have a distal portion with a coil shaped body member and a proximal portion which contacts the sclera. In one aspect, the coil-shaped body member includes a unique configurat... | 07/29/2010 |
| 20100189766 | SUBSTANCE DELIVERING PUNCTUM IMPLANTS AND METHODS Substance delivering punctum plug devices and related methods for treating disorders and diseases of the eye. Some embodiments of the device maximize dissolution of the substance in tears and/or other fluid(s) that distribute to the anterior surface of the eye so as to ... | 07/29/2010 |
| 20100178315 | POLYMERIC SYSTEMS FOR CONTROLLED DRUG THERAPY Polymeric compositions containing a high percentage of bound alkyl ether segments provide matrices and membranes for the controlled release of drugs and medicinal agents. The polymeric compositions are prepared by the polymerization of ethylenically unsaturated alkyl et... | 07/15/2010 |
| 20100129424 | Contact drug delivery system A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structural... | 05/27/2010 |
| 20100087474 | MATERIALS AND METHODS FOR ENHANCED DEGRADATION OF MUTANT PROTEINS ASSOCIATED WITH HUMAN DISEASE The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by enhancing the degradation of misfolded proteins in vivo.... | 04/08/2010 |
| 20100080840 | Hybrid superporous hydrogel scaffold for cornea regeneration The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous hydrogen matrix with collagen and cells embedded within the pores of the matrix.... | 04/01/2010 |
| 20100074942 | DEVICE AND METHOD FOR INTRAOCULAR DRUG DELIVERY Intraocular devices having a drug delivery construct attached thereto, and methods for using the devices for intraocular drug delivery and the treatment and/or prevention of conditions.... | 03/25/2010 |
| 20100040669 | Non-Invasive Ocular Delivery of Rapamycin Methods and systems for preventing or treating various ocular conditions are disclosed and described. In one aspect, for example, a method for noninvasively delivering a water insoluble macrolide into an eye of a subject for treatment of an ocular condition is provided.... | 02/18/2010 |
| 20100040670 | DRUG DELIVERY VIA OCULAR IMPLANT A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via... | 02/18/2010 |
| 20100034870 | COMPOSITE LACRIMAL INSERT AND RELATED METHODS Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.... | 02/11/2010 |
